Amgen, Teijin link for RORy autoimmune candidates
This article was originally published in Scrip
Executive Summary
Amgen and the Japanese group Teijin have joined forces to conduct discovery research in a promising avenue for the treatment of autoimmune disorders, the modulation of retinoic acid-related orphan receptor-gamma (RORy).